Dialysis News and Research

Latest Dialysis News and Research

DaVita Clinical Research announces expansion of clinical trials capabilities in Europe

DaVita Clinical Research (DCR), a specialty contract research organization with services spanning a broad spectrum of drug and device development, today announced an expansion of its clinical trials capabilities in Europe.

28 May 2015

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo.

19 May 2015

WHO Regional Office for the Eastern Mediterranean press release: WHO delivers additional medicines and medical supplies into Yemen

WHO is also providing a shipment of anti-malaria medicines from the Global Fund to Fight AIDS, Tuberculosis and Malaria sufficient for 44 950 treatment courses of malaria...

15 May 2015

DaVita HealthCare Partners recognizes May as Employee Health Month

DaVita HealthCare Partners Inc., one of the nation's largest and most innovative health care communities, recognizes the month of May as Employee Health Month. The health of teammates is vital in helping to ensure they can provide the best quality of care for DaVita HealthCare Partners' patients.

7 May 2015

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

Phosphate Therapeutics Limited, a development-stage specialty pharmaceuticals company, today announces positive results from the PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD).

7 May 2015

DaVita Way of Giving program receives Communitas Award

DaVita HealthCare Partners Inc., one of the nation's largest and most innovative health care communities, today announced that the company received a Communitas Award for its DaVita Way of Giving program.

22 Apr 2015

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS).

21 Apr 2015

Bayshore HealthCare achieves BPSO designation

Bayshore HealthCare Ltd. is pleased to announce that it has achieved the designation of Best Practice Spotlight Organization presented by the Registered Nurses' Association of Ontario.

20 Apr 2015

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Pharmalink AB, a specialty pharma company, today announces that the NEFIGAN Trial of Nefecon for the treatment of primary IgA nephropathy has fully met its primary efficacy endpoint at a planned interim analysis and been stopped early with respect to statistical analysis of the endpoint.

14 Apr 2015

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation...

13 Apr 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that clinical data for simeprevir, its NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver taking place in Vienna from April 22-26.

8 Apr 2015

New oral drug shows promise in patients with chronic kidney disease

Patients with chronic kidney disease may be treated with a class of medications called Renin Angiotensin Aldosterone System inhibitors (RAASI's). Although these drugs protect the heart and kidney, a significant percentage of patients develop a dangerous side effect -- high potassium levels in the blood (hyperkalemia).

31 Mar 2015

Six winners share £2 million to develop cutting-edge technology to prevent kidney disease

SIX winners, announced today, will receive a share of over £2 million as part of a Small Business Research Initiative competition aimed at developing cutting-edge technology solutions to help kidney patients.

31 Mar 2015

DaVita Kidney Care celebrates its dietitians and social workers

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, is celebrating its more than 3,600 dietitians and social workers during March for their distinctive and important roles in patient care.

30 Mar 2015

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

25 Mar 2015

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

TVA Medical, Inc., today announced promising results from a clinical study evaluating a novel hemodialysis access technique that has the potential to revolutionize vascular access for patients with chronic kidney disease without the use of traditional open surgery.

25 Mar 2015

DCR representatives to present health-related quality posters at NKF's 2015 Spring Clinical Meeting

DaVita Clinical Research, a specialty contract research organization with services spanning the full spectrum of drug and device development and subsidiary of DaVita HealthCare Partners Inc., today announced that company representatives will present health-related quality posters at National Kidney Foundation's 2015 Spring Clinical Meeting, which takes place March 25-29, 2015 in Dallas.

25 Mar 2015

Testing APOL1 gene variants in deceased kidney donors may improve transplant outcomes

Kidney transplantation outcomes from deceased African-American donors may improve through rapid testing for apolipoprotein L1 gene (APOL1) renal risk variants at the time of organ recovery, according to a new study led by researchers at Wake Forest Baptist Medical Center.

25 Mar 2015

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid.

23 Mar 2015

DaVita HealthCare Partners named Metro Denver's healthiest extra-large employer

DaVita HealthCare Partners Inc., one of the nation's largest and most innovative health care communities, has been recognized by the Denver Business Journal as Metro Denver's healthiest extra-large employer. This is the fourth consecutive year the company has topped the list because of its commitment to teammate health and wellness.

23 Mar 2015

Dialysis News and Research

Latest Dialysis News and Research

DaVita Clinical Research announces expansion of clinical trials capabilities in Europe

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

WHO Regional Office for the Eastern Mediterranean press release: WHO delivers additional medicines and medical supplies into Yemen

DaVita HealthCare Partners recognizes May as Employee Health Month

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

DaVita Way of Giving program receives Communitas Award

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Bayshore HealthCare achieves BPSO designation

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

New oral drug shows promise in patients with chronic kidney disease

Six winners share £2 million to develop cutting-edge technology to prevent kidney disease

DaVita Kidney Care celebrates its dietitians and social workers

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

DCR representatives to present health-related quality posters at NKF's 2015 Spring Clinical Meeting

Testing APOL1 gene variants in deceased kidney donors may improve transplant outcomes

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

DaVita HealthCare Partners named Metro Denver's healthiest extra-large employer

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Dialysis News and Research

Latest Dialysis News and Research

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Newsletters you may be interested in